Dupixent 200 mg/1.14mL

Dupilumab, the active ingredient in Dupixent, is an interleukin-4 receptor alpha antagonist presented as a 200 mg/1.14 mL solution for subcutaneous use. It is used to treat moderate-to-severe atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps in adults and children.

GNH USA supplies Dupixent 200 mg/1.14mL as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide.

Dupixent 200 mg/1.14mL is primarily used to manage inflammatory conditions by targeting specific pathways involved in inflammation. It is prescribed for the following conditions:

- Moderate-to-severe atopic dermatitis (eczema): Reduces symptoms and improves quality of life in adults and children. - Asthma: Used as an add-on treatment for severe asthma not adequately controlled by other medications. - Chronic rhinosinusitis with nasal polyps: Helps manage symptoms when other treatments have not been effective.

Dupixent 200 mg/1.14mL may cause several side effects, ranging from common to serious. Common Side Effects: - Injection site reactions - Eye and eyelid inflammation - Cold symptoms - Joint pain - Temporary increase in eosinophils

Serious or Rare Side Effects: - Allergic reactions, including anaphylaxis - Conjunctivitis and keratitis - Herpes zoster - Joint pain and mobility issues - Elevated liver enzymes

Dupixent should be used with caution and under the guidance of a healthcare provider. Important precautions include: - Inform your healthcare provider about all medications you are taking, especially those that suppress the immune system. - Avoid using live vaccines while on Dupixent without medical advice. - Monitor for signs of allergic reactions or infections. - Use exactly as prescribed and do not shake the syringe before use. - Store at room temperature: Protect from light and do not freeze.

Dupixent may interact with other medications, particularly those that affect the immune system. Major Interactions (Avoid): - Live vaccines: Avoid concurrent use due to potential reduced vaccine efficacy and increased risk of infection. - Biologic therapies: May increase the risk of infections when used together.

Moderate Interactions (Monitor Closely): - Systemic corticosteroids: Monitor for signs of infection or reduced efficacy. - Other immunosuppressants: Increased risk of infections and other immune-related side effects.